BioCode gold-nanobeacon for the detection of fusion transcripts causing chronic myeloid leukemia,
Cordeiro, M., Giestas L., Lima {J. C. }, and Baptista {P. M. V. }
, Journal of Nanobiotechnology, may, Volume 14, Number 1, (2016)
AbstractBACKGROUND: Gold-nanobeacons (Au-nanobeacons) have proven to be versatile systems for molecular diagnostics and therapeutic actuators. Here, we present the development and characterization of two gold nanobeacons combined with Förster resonance energy transfer (FRET) based spectral codification for dual mode sequence discrimination. This is the combination of two powerful technologies onto a single nanosystem.RESULTS: We proved this concept to detect the most common fusion sequences associated with the development of chronic myeloid leukemia, e13a2 and e14a2. The detection is based on spectral shift of the donor signal to the acceptor, which allows for corroboration of the hybridization event. The Au-nanobeacon acts as scaffold for detection of the target in a homogenous format whose output capability (i.e. additional layer of information) is potentiated via the spectral codification strategy.CONCLUSIONS: The spectral coded Au-nanobeacons permit the detection of each of the pathogenic fusion sequences, with high specificity towards partial complementary sequences. The proposed BioCode Au-nanobeacon concept provides for a nanoplatform for molecular recognition suitable for cancer diagnostics.
Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology,
Mendes, Rita, Carreira Bárbara, Baptista {Pedro V. }, and Fernandes {Alexandra R. }
, Expert Review of Precision Medicine and Drug Development, mar, Volume 1, Number 2, p.155–168, (2016)
AbstractLung cancer is the leading cause of cancer-related mortality in the world, non-small lung cancer (NSCLC) is the most frequent subtype (85% of the cases). Within this subtype, adenocarcinoma and squamous cell carcinoma are the most frequent. New therapeutic strategies based on targeted delivery of drugs have relied on the use of biomarkers derived from the patients’ molecular profiling. Several biomarkers have been found to be useful for use as targets for precision therapy in NSCLC, such as mutations in the epidermal growth factor receptor, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, anaplastic lymphoma kinase, mesenchymal-epithelial transition factor receptor tyrosine kinase, BRAF, c-ros oncogene 1, P53 and phosphatase with tensin homology. Current developments in Nanomedicine have allowed for multifunctional systems capable of delivering therapeutics with increased precision to the target site/tissue, while simultaneously assisting in diagnosis. Here, we review the use of biomarkers in nanotechnology translation in NSCLC management.
A novel mutation in CEBPA gene in a patient with acute myeloid leukemia,
Vinhas, Raquel, Tolmatcheva Anna, Canto Rafaela, Ribeiro Patricia, Lourenco Alexandra, {de Sousa} {Aida Botelho}, Baptista {Pedro Miguel Ribeiro Viana}, and de Fernandes {Maria Alexandra Núncio Carvalho Ramos}
, Leukemia & Lymphoma, mar, Volume 57, Number 3, p.711–713, (2016)
Abstractn/a
Colorimetric assessment of BCR-ABL1 transcripts in clinical samples via gold nanoprobes,
Vinhas, Raquel, Correia Claudia, Ribeiro Patricia, Lourenco Alexandra, {de Sousa} {Aida Botelho}, de Fernandes {Maria Alexandra Núncio Carvalho Ramos}, and Baptista {Pedro Miguel Ribeiro Viana}
, Analytical and Bioanalytical Chemistry, jul, Volume 408, Number 19, p.5277–5284, (2016)
AbstractGold nanoparticles functionalized with thiolated oligonucleotides (Au-nanoprobes) have been used in a range of applications for the detection of bioanalytes of interest, from ions to proteins and DNA targets. These detection strategies are based on the unique optical properties of gold nanoparticles, in particular, the intense color that is subject to modulation by modification of the medium dieletric. Au-nanoprobes have been applied for the detection and characterization of specific DNA sequences of interest, namely pathogens and disease biomarkers. Nevertheless, despite its relevance, only a few reports exist on the detection of RNA targets. Among these strategies, the colorimetric detection of DNA has been proven to work for several different targets in controlled samples but demonstration in real clinical bioanalysis has been elusive. Here, we used a colorimetric method based on Au-nanoprobes for the direct detection of the e14a2 BCR-ABL fusion transcript in myeloid leukemia patient samples without the need for retro-transcription. Au-nanoprobes directly assessed total RNA from 38 clinical samples, and results were validated against reverse transcription-nested polymerase chain reaction (RT-nested PCR) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The colorimetric Au-nanoprobe assay is a simple yet reliable strategy to scrutinize myeloid leukemia patients at diagnosis and evaluate progression, with obvious advantages in terms of time and cost, particularly in low- to medium-income countries where molecular screening is not routinely feasible.
Gold nanoparticles for diagnostics: Advances towards points of care,
Cordeiro, Milton, Pedrosa Pedro, Carlos {Fábio Ferreira}, Lopez António, and Baptista {Pedro Viana}
, Diagnostics, dec, Volume 6, Number 4, (2016)
AbstractThe remarkable physicochemical properties of gold nanoparticles (AuNPs) have prompted developments in the exploration of biomolecular interactions with AuNP-containing systems, in particular for biomedical applications in diagnostics. These systems show great promise in improving sensitivity, ease of operation and portability. Despite this endeavor, most platforms have yet to reach maturity and make their way into clinics or points of care (POC). Here, we present an overview of emerging and available molecular diagnostics using AuNPs for biomedical sensing that are currently being translated to the clinical setting.
Infection of human keratinocytes by Streptococcus dysgalactiae subspecies dysgalactiae isolated from milk of the bovine udder,
Roma-Rodrigues, Catarina, Alves-Barroco Cynthia, Raposo {Luis R. }, Costa {Mafalda N. }, Fortunato Elvira, Baptista {Pedro Miguel Ribeiro Viana}, de Fernandes {Maria Alexandra Núncio Carvalho Ramos}, and Santos-Sanches Ilda
, Microbes And Infection, apr, Volume 18, Number 4, p.290–293, (2016)
AbstractStreptococcus dysgalactiae subsp. dysgalactiae (SDSD) are considered exclusive animal pathogens; however, a putative zoonotic upper limb cellulitis, a prosthetic joint infection and an infective endocarditis were described in humans. To unravel if bovine SDSD isolates are able to infect human cells, the adherence and internalization to human primary keratinocytes of two bovine SDSD strains isolated from milk collected from udder were analyzed. Bacterial adhesion assays and confocal microscopy indicate a high adherence and internalization of SDSD isolates to human cells, suggesting for the first time the ability of bovine isolates to infect human cells. (C) 2015 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
In vitro and in vivo biological characterization of the anti-proliferative potential of a cyclic trinuclear organotin(IV) complex,
Martins, Marta, Baptista P. V., Mendo {Ana Soraia}, Correia C., Videira Paula, Rodrigues A. S., Muthukumaran Jayaraman, Santos-Silva Teresa, Silva Ana, {Guedes da Silva} Fatima {M. C. }, Gigante Joana, Duarte Antonio, Gajewska Malgorzata, and Fernandes A. R.
, Molecular Biosystems, Volume 12, Number 3, p.1015–1023, (2016)
AbstractIdentification of novel molecules that can selectively inhibit the growth of tumor cells, avoid causing side effects to patients and/or intrinsic or acquired resistance, usually associated with common chemotherapeutic agents, is of utmost importance. Organometallic compounds have gained importance in oncologic chemotherapy, such as organotin(IV) complexes. In this study, we assessed the anti-tumor activity of the cyclic trinuclear organotin(IV) complex with an aromatic oximehydroxamic acid group [nBu(2)Sn(L)](3)(H2L = N,2-dihydroxy-5-[N-hydroxyethanimidoyl]benzamide) - MG85 - and provided further characterization of its biological targets. We have previously shown the high anti-proliferative activity of this complex against human colorectal and hepatocellular carcinoma cell lines and lower cytotoxicity in neonatal non-tumor fibroblasts. MG85 induces tumor cell apoptosis and down-regulation of proteins related to tubulin dynamics (TCTP and COF1). Further characterization included the: (i) evaluation of interference in the cell cycle progression, including the expression of critical genes; (ii) affinity to DNA and the corresponding mode of binding; (iii) genotoxic potential in cells with deficient DNA repair pathways; and (iv) in vivo tumor reduction efficiency using mouse colorectal carcinoma xenografts.